Abivax
Created in 2013
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,288 8,591Activities
Technologies
Entity types
Location
Corporate Office, 11 Bd Haussmann 7, 75009 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 68
SIREN
799363718Engaged corporates
8
4 4Added in Motherbase
3 years, 1 month ago
biotech Value proposition
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.
R&D, Inflammatory Bowel Desease, Biotechnology, Innovation, Ulcerative colitis, and Crohn's diseaseOriginal language
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.
Home - Abivax
https://www.abivax.com/?lang=fr
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Partnership Not event 31 May 2022 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 24 Oct 2023 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 19 Sep 2017 | | |
 Avolta Finance, Investment Banking | Avolta Finance, Investment Banking | Other 31 Aug 2022 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 3 Nov 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 13 Jun 2017 | | |
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 18 Nov 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Not capitalistic Not partnership Event 12 May 2017 | | |